Publications by authors named "Kristina Prager"
Article Synopsis
- The study evaluated the long-term sustainability of neutralizing antibodies against HPV in participants from two major vaccine trials (PATRICIA and FUTURE II) conducted in Finland, focusing on girls who were vaccinated between 2002 and 2005.
- Researchers analyzed over 1,100 serum samples collected from participants up to 12 years post-vaccination to assess the presence of these antibodies against various HPV types.
- Results showed that while neutralizing antibodies were generally detectable for a decade after vaccination, a notable proportion of samples from quadrivalent vaccine recipients did not maintain protective levels.
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine.
View Article and Find Full Text PDFHuman herpesviruses (HHV) cause a variety of clinically relevant conditions upon primary infection of typically young and immunocompetent hosts. Both primary infection and reactivation after latency can lead to more severe disease, such as encephalitis, congenital defects and cancer. Infections with HHV are also associated with cardiovascular and neurodegenerative disease.
View Article and Find Full Text PDF